Second-line-like immunotherapy and chemo for metastatic pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 trial studies a combination of immunotherapy, a blood-vessel/immune signal blocker, and chemotherapy for people with metastatic pancreatic adenocarcinoma. It may help shrink tumors and improve control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven metastatic pancreatic adenocarcinoma (stage IV), and it must be confirmed by the treating pathologist
- You are at least 18 years old and generally able to do daily activities (ECOG performance status 0–1)
- You have enough blood counts and organ function on recent lab tests (for example, platelets, kidney function, and liver tests not too high)
- Your tumor is measurable and can be accessed for a fresh biopsy before starting treatment
- You have not had prior chemo, immune checkpoint drugs (like PD-1/PD-L1 or CTLA-4), or investigational cancer drugs for pancreatic cancer
- You can use effective birth control and will not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This Phase 2 study tests a combination of medicines (including valproic acid and a statin) along with standard chemotherapy for people with newly diagnosed metastatic pancreatic cancer. The goal is to improve cancer control before any prior pancreatic cancer treatments and to see how well the medicines work and are tolerated.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a combination of immunotherapy (penpulimab), a targeted therapy (anlotinib), and two chemotherapy drugs (nab-paclitaxel and gemcitabine) as a first treatment for pancreatic cancer that has spread. It aims to see if this new combination works better than standard care.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.